{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:51:32Z","timestamp":1782211892555,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1120331"],"award-info":[{"award-number":["APP1120331"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40273-026-01609-0","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:11:19Z","timestamp":1773367879000},"page":"839-849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-2858","authenticated-orcid":false,"given":"An","family":"Tran-Duy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Asbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty L.","family":"Buising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Adie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnthan","family":"Mulford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Harris-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Roney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"de Steiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha N.","family":"Peel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ASAP Trial Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"5","key":"1609_CR1","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2106\/00004623-200405000-00012","volume":"86","author":"O Ethgen","year":"2004","unstructured":"Ethgen O, Bruy\u00e8re O, Richy F, Dardennes C, Reginster J-Y. Health-related quality of life in total hip and total knee arthroplasty: a qualitative and systematic review of the literature. JBJS. 2004;86(5):963\u201374.","journal-title":"JBJS"},{"issue":"6","key":"1609_CR2","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2019-216515","volume":"79","author":"S Safiri","year":"2020","unstructured":"Safiri S, Kolahi A-A, Smith E, Hill C, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of osteoarthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease Study 2017. Ann Rheum Dis. 2020;79(6):819\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1609_CR3","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.3899\/jrheum.170990","volume":"46","author":"JA Singh","year":"2019","unstructured":"Singh JA, Yu S, Chen L, Cleveland JD. Rates of total joint replacement in the United States: future projections to 2020\u20132040 using the national inpatient sample. J Rheum. 2019;46(9):1134\u201340.","journal-title":"J Rheum"},{"key":"1609_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-019-2411-9","volume":"20","author":"IN Ackerman","year":"2019","unstructured":"Ackerman IN, Bohensky MA, Zomer E, Tacey M, Gorelik A, Brand CA, et al. The projected burden of primary total knee and hip replacement for osteoarthritis in Australia to the year 2030. BMC Musculoskelet Disord. 2019;20:1\u201310.","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"1609_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.arth.2012.02.022","volume":"27","author":"SM Kurtz","year":"2012","unstructured":"Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;27(8):61-5. e1.","journal-title":"J Arthroplasty"},{"issue":"8","key":"1609_CR6","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1001\/jamasurg.2017.0904","volume":"152","author":"SI Berr\u00edos-Torres","year":"2017","unstructured":"Berr\u00edos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg. 2017;152(8):784\u201391.","journal-title":"JAMA Surg"},{"issue":"5","key":"1609_CR7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1016\/j.arth.2020.12.005","volume":"36","author":"A Premkumar","year":"2021","unstructured":"Premkumar A, Kolin DA, Farley KX, Wilson JM, McLawhorn AS, Cross MB, et al. Projected economic burden of periprosthetic joint infection of the hip and knee in the United States. J Arthroplasty. 2021;36(5):1484-9. e3.","journal-title":"J Arthroplasty"},{"issue":"9","key":"1609_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.arth.2025.03.057","volume":"40","author":"AS Hammat","year":"2025","unstructured":"Hammat AS, Gnanamanickam ES, Cho CH, Ramasamy B, Nelson R, Campbell DG, et al. Diagnosis and treatment influence hospital costs of revision total hip arthroplasty: a systematic review and meta-analysis. J Arthroplasty. 2025;40(9):2423\u201331.","journal-title":"J Arthroplasty"},{"issue":"12","key":"1609_CR9","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S1473-3099(16)30398-X","volume":"16","author":"B Allegranzi","year":"2016","unstructured":"Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e276\u201387.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1609_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1089\/sur.2013.9999","volume":"14","author":"DW Bratzler","year":"2013","unstructured":"Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013;14(1):73\u2013156.","journal-title":"Surg Infect (Larchmt)"},{"issue":"5","key":"1609_CR11","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1128\/AAC.06246-11","volume":"56","author":"TN Peel","year":"2012","unstructured":"Peel TN, Cheng AC, Buising KL, Choong PF. Microbiological aetiology, epidemiology, and clinical profile of prosthetic joint infections: are current antibiotic prophylaxis guidelines effective? Antimicrob Agents Chemother. 2012;56(5):2386\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1609_CR12","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1086\/675289","volume":"35","author":"SI Berr\u00edos-Torres","year":"2014","unstructured":"Berr\u00edos-Torres SI, Sarah HY, Bratzler DW, Ma A, Mu Y, Zhu L, et al. Activity of commonly used antimicrobial prophylaxis regimens against pathogens causing coronary artery bypass graft and arthroplasty surgical site infections in the United States, 2006\u20132009. Infect Control Hosp Epidemiol. 2014;35(3):231\u20139.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"2","key":"1609_CR13","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1128\/AAC.03949-14","volume":"59","author":"E Tornero","year":"2015","unstructured":"Tornero E, Garc\u00eda-Ramiro S, Mart\u00ednez-Pastor JC, Bori G, Bosch J, Morata L, et al. Prophylaxis with teicoplanin and cefuroxime reduces the rate of prosthetic joint infection after primary arthroplasty. Antimicrob Agents Chemother. 2015;59(2):831\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"1609_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/ajhp\/56.18.1839","volume":"56","author":"Pharmacists ASoH-S","year":"1999","unstructured":"Pharmacists ASoH-S. ASHP therapeutic guidelines on antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 1999;56:1839\u201388.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"1609_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.amjsurg.2005.01.015","volume":"189","author":"DW Bratzler","year":"2005","unstructured":"Bratzler DW, Houck PM, Workgroup SIPGW. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Am J Surg. 2005;189(4):395\u2013404.","journal-title":"Am J Surg"},{"issue":"8","key":"1609_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.arth.2012.03.040","volume":"27","author":"EB Smith","year":"2012","unstructured":"Smith EB, Wynne R, Joshi A, Liu H, Good RP. Is it time to include vancomycin for routine perioperative antibiotic prophylaxis in total joint arthroplasty patients? J Arthroplasty. 2012;27(8):55\u201360.","journal-title":"J Arthroplasty"},{"issue":"7","key":"1609_CR17","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.arth.2018.03.009","volume":"33","author":"JR Burger","year":"2018","unstructured":"Burger JR, Hansen BJ, Leary EV, Aggarwal A, Keeney JA. Dual-agent antibiotic prophylaxis using a single preoperative vancomycin dose effectively reduces prosthetic joint infection rates with minimal renal toxicity risk. J Arthroplasty. 2018;33(7):S213\u20138.","journal-title":"J Arthroplasty"},{"issue":"7","key":"1609_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002340","volume":"14","author":"W Branch-Elliman","year":"2017","unstructured":"Branch-Elliman W, Ripollone JE, O\u2019Brien WJ, Itani KM, Schweizer ML, Perencevich E, et al. Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: a national propensity-score-adjusted retrospective cohort study. PLoS Med. 2017;14(7):e1002340.","journal-title":"PLoS Med"},{"issue":"10","key":"1609_CR19","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1007\/s11999-012-2255-1","volume":"470","author":"A Sewick","year":"2012","unstructured":"Sewick A, Makani A, Wu C, O\u2019Donnell J, Baldwin KD, Lee G-C. Does dual antibiotic prophylaxis better prevent surgical site infections in total joint arthroplasty? Clin Orthop Relat Res. 2012;470(10):2702\u20137.","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"1609_CR20","doi-asserted-by":"publisher","first-page":"970","DOI":"10.2106\/JBJS.M.00663","volume":"96","author":"B Ponce","year":"2014","unstructured":"Ponce B, Raines BT, Reed RD, Vick C, Richman J, Hawn M. Surgical site infection after arthroplasty: comparative effectiveness of prophylactic antibiotics: do surgical care improvement project guidelines need to be updated? J Bone Jt Surg Am. 2014;96(12):970\u20137.","journal-title":"J Bone Jt Surg Am"},{"issue":"1","key":"1609_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s42836-023-00222-2","volume":"6","author":"SS Bains","year":"2024","unstructured":"Bains SS, Dubin JA, Hameed D, Chen Z, Moore MC, Shrestha A, et al. Addition of vancomycin to cefazolin is often unnecessary for preoperative antibiotic prophylaxis during total joint arthroplasties. Arthroplasty. 2024;6(1):20.","journal-title":"Arthroplasty"},{"issue":"16","key":"1609_CR22","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1056\/NEJMoa2301401","volume":"389","author":"TN Peel","year":"2023","unstructured":"Peel TN, Astbury S, Cheng AC, Paterson DL, Buising KL, Spelman T, et al. Trial of vancomycin and cefazolin as surgical prophylaxis in arthroplasty. N Engl J Med. 2023;389(16):1488\u201398.","journal-title":"N Engl J Med"},{"issue":"11","key":"1609_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033718","volume":"9","author":"T Peel","year":"2019","unstructured":"Peel T, Astbury S, Cheng AC, Paterson D, Buising K, Spelman T, et al. Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial. BMJ Open. 2019;9(11):e033718.","journal-title":"BMJ Open"},{"key":"1609_CR24","unstructured":"Pharmaceutical Benefits Scheme (PBS). Vancomycin. 2024. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/2269K-2270L-3113W-3114X-3130R-3131T-3323X-5083M. Accessed 1 August 2024."},{"key":"1609_CR25","unstructured":"Pharmaceutical Benefits Scheme (PBS). Cefazolin. 2024. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/12115P-12118T-1256D-1797N-1799Q-5477G. Accessed 1 August 2024."},{"key":"1609_CR26","unstructured":"Australian Government Services Australia. Pharmaceutical Benefits Schedule Item Reports. 2024. Available from: http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/pbs_item.jsp. Accessed 1 August 2024."},{"key":"1609_CR27","unstructured":"Australian Bureau of Statistics (ABS). Consumer Price Index, Australia. 2025. Available from: https:\/\/www.abs.gov.au\/statistics\/economy\/price-indexes-and-inflation\/consumer-price-index-australia\/latest-release.  Accessed 1 Jan 2025."},{"issue":"6","key":"1609_CR28","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.jval.2011.04.009","volume":"14","author":"R Viney","year":"2011","unstructured":"Viney R, Norman R, King MT, Cronin P, Street DJ, Knox S, et al. Time trade-off derived EQ-5D weights for Australia. Value Health. 2011;14(6):928\u201336.","journal-title":"Value Health"},{"issue":"3","key":"1609_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1214\/ss\/1032280214","volume":"11","author":"TJ DiCiccio","year":"1996","unstructured":"DiCiccio TJ, Efron B. Bootstrap confidence intervals. Stat Sci. 1996;11(3):189\u2013228.","journal-title":"Stat Sci"},{"issue":"4","key":"1609_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W","volume":"6","author":"AH Briggs","year":"1997","unstructured":"Briggs AH, Wonderling DE, Mooney CZ. Pulling cost\u2010effectiveness analysis up by its bootstraps: a non\u2010parametric approach to confidence interval estimation. Health Econ. 1997;6(4):327\u201340.","journal-title":"Health Econ"},{"issue":"5","key":"1609_CR31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/0272989X08315247","volume":"28","author":"AH Harris","year":"2008","unstructured":"Harris AH, Hill SR, Chin G, Li JJ, Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med Decis Making. 2008;28(5):713\u201322.","journal-title":"Med Decis Making"},{"issue":"7","key":"1609_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.zefq.2014.08.020","volume":"108","author":"R Lopert","year":"2014","unstructured":"Lopert R, Viney R. Revolution then evolution: the advance of health economic evaluation in Australia. Z Evid Fortbild Qual Gesundhwes. 2014;108(7):360\u20136.","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"issue":"8","key":"1609_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","volume":"21","author":"S Wang","year":"2018","unstructured":"Wang S, Gum D, Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC\u2014does the presence of an explicit threshold affect the ICER proposed? Value Health. 2018;21(8):938\u201343.","journal-title":"Value Health"},{"issue":"8","key":"1609_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/hec.635","volume":"10","author":"E Fenwick","year":"2001","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: The role of cost\u2010effectiveness acceptability curves. Health Econ. 2001;10(8):779\u201387.","journal-title":"Health Econ"},{"key":"1609_CR35","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2025 01 Feb 2026]; Available from: https:\/\/www.R-project.org\/."},{"key":"1609_CR36","doi-asserted-by":"crossref","unstructured":"Stolz M, Schmetsdorf J, Tomsic I, von Lengerke T, Chaberny IF, Krauth C. Costs of surgical site infections in orthopaedic and trauma surgery: a systematic review. J Hosp Infect. 2025;169:42-58.","DOI":"10.1016\/j.jhin.2025.11.008"},{"issue":"5","key":"1609_CR37","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jiph.2023.03.018","volume":"16","author":"R Royle","year":"2023","unstructured":"Royle R, Gillespie BM, Chaboyer W, Byrnes J, Nghiem S. The burden of surgical site infections in Australia: a cost-of-illness study. J Infect Public Health. 2023;16(5):792\u20138.","journal-title":"J Infect Public Health"},{"key":"1609_CR38","unstructured":"Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2024 Annual Report. 2024 16 June 2025]; Available from: https:\/\/aoanjrr.sahmri.com\/web\/guest\/annual-reports-2024."},{"issue":"6","key":"1609_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics. 2020;38(6):575\u201391.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"1609_CR40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s40273-022-01172-4","volume":"40","author":"MF Janssen","year":"2022","unstructured":"Janssen MF, Buchholz I, Golicki D, Bonsel GJ. Is EQ-5D-5L better than EQ-5D-3L over time? A head-to-head comparison of responsiveness of descriptive systems and value sets from nine countries. Pharmacoeconomics. 2022;40(11):1081\u201393.","journal-title":"Pharmacoeconomics"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01609-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01609-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:42:48Z","timestamp":1782211368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01609-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1609"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01609-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation\n                      : AT-D, TNP.\n                      Data Collection & Curation\n                      : All authors.\n                      Methodology and Data Analysis\n                      :\n                      AT-D.\n                      Interpretation\n                      : All authors.\n                      Writing \u2013 Original Draft\n                      : AT-D.\n                      Writing \u2013 Review\n                      : All authors.\n                      Critical Revision\n                      : AT-D.\n                      Supervision\n                      : AT-D, RdS, TNP.\n                      Funding Acquisition:\n                      TNP, the ASAP Trial Group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"David Paterson served as a member of the Scientific Advisory Board for the AMR Action Fund and as a consultant for Aurobac, BioVersys, CARB-X, Entasis, and Spero. He has received research funding from Merck, Pfizer Inc., and Shionogi, as well as honoraria from bioM\u00e9rieux, Merck, and Pfizer Inc. for lectures on antimicrobial resistance. Trisha Peel is a section editor for Native Vertebral Osteomyelitis and Linezolid for UpToDate.\u00a0All other authors have no conflicts of interest relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"De-identified data are available upon request to researchers with an approved proposal, contingent on signing a data access agreement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}